On August 26, Biohaven (NYSE:BHVN) and SK Biopharmaceuticals announced a global licensing agreement covering opakalim, Biohaven’s lead epilepsy candidate, in a deal worth up to $795 million plus royalties. SK Biopharmaceuticals picks up exclusive worldwide rights to Biohaven’s Kv7 ion channel platform, while Biohaven walks away with $400 million in near-term cash. The timing lines up with an August 10, 2026 earnings report that showed Biohaven still losing well over $100 million a quarter, and the gap between those two dates explains a lot about why this deal happened now.
Money Without Losing The Upside
SK Biopharmaceuticals will pay up to $795 million in upfront and milestone payments connected to the Kv7 platform, on top of tiered royalties on US net sales of opakalim that range from the mid-teens to low twenties. Biohaven collects $350 million at closing and another $50 million in 2027, with as much as $150 million more available through development and regulatory milestones plus royalties on global sales. SK Biopharmaceuticals is also taking over Kv7 program costs going forward, including certain Knopp Biosciences obligations. CEO Vlad Coric described the structure as proof Biohaven can monetize its pipeline through partnerships rather than leaning on public markets for cash.
The deal only makes sense because opakalim looks like it works. In a proof-of-concept study in idiopathic generalized epilepsy, the median time to a second generalized tonic-clonic seizure stretched to 141 days on opakalim versus 47 days on placebo, and a third of patients made it through the full 24 weeks without a second seizure. In focal epilepsy, 54% of patients in an open-label extension study saw at least a 50% drop in seizure frequency over any six months, in a group of more than 100 patients.
Opakalim is also designed as a once-daily pill with no titration required, a real edge over older antiseizure drugs. Pairing that data with SK Biopharmaceuticals, the company behind XCOPRI and the only firm to bring a new focal-seizure drug to the US market since 2016, gives Opakalim a commercial path Biohaven would have struggled to build alone. The cash also buys runway for the rest of the pipeline, including protein degraders BHV-1300 and BHV-1400, which have shown rapid, selective reductions in disease-driving antibodies in Graves’ disease and IgA nephropathy with clean safety data across nearly 200 patients dosed.
Handing Off The Big Payoff
Biohaven is giving up full ownership of an asset it now believes could be a major seller. Royalties in the mid-teens to low twenties are real money, but they are a fraction of what outright ownership of an approved epilepsy drug would be worth, and $50 million of the $400 million upfront does not arrive until 2027. The Knopp Biosciences obligations SK Biopharmaceuticals is absorbing, worth up to $245 million plus mid-single-digit royalties, are a reminder that other parties already have claims on opakalim’s future revenue before Biohaven sees a dollar of profit from it.
None of this changes the fact that Biohaven is still a cash-burning clinical company. The August 10, 2026 report showed a $137.3 million net loss for the quarter, or $0.91 per share, against $270.5 million in cash, cash equivalents, and marketable securities as of June 30. Topline results from the pivotal RISE3 trial in focal epilepsy, the data this whole licensing deal is built around, are not expected until the second half of 2026, meaning the asset SK Biopharmaceuticals just paid for has not cleared its final regulatory hurdle. Much of the rest of the pipeline, from the BHV-1530 antibody-drug conjugate to the newly dosed BHV-8100, is still in early-stage trials with years to go before any of it could produce revenue.
What The Market Is Pricing In
Hedge fund ownership of Biohaven held steady at 47 funds in the most recent quarter, unchanged from the prior quarter, suggesting institutional conviction neither grew nor faded heading into this deal. Short interest sits at 15.09% of float, a level that points to a sizable bear camp actively positioned against the stock. That mix suggests that the market has not yet settled on whether the SK Biopharmaceuticals deal changes Biohaven’s story. A stock this heavily shorted can also move sharply if the RISE3 data lands well, since short sellers would be forced to cover into good news.
Where This Leaves Shareholders
Biohaven has traded a slice of opakalim’s long-term upside for immediate, non-dilutive cash and a commercial partner with a track record in epilepsy. That trade looks smart if RISE3 reads out well later in 2026 and opakalim reaches patients faster than Biohaven could manage alone, but less smart if the royalty stream ends up worth far less than outright ownership would have been. For the bulls, the case rests on strong seizure-reduction data repeating in the pivotal trial and the protein degrader programs converting on a similar timeline.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Follow Insider Monkey on Google News.
Hedge Fund Resource Center